Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer

European Journal of Cancer Care

Volumn 16, Issue 6, 2007, Pages 539-542

  Heras, P ^a,b   Karagiannis, S ^b   Kritikos, K ^b   Hatzopoulos, A ^a,b   Mitsibounas, D ^b  

^a General Hospital of Nafplio   (Greece)

^b Hellenic Medical Society for the Study of Psychosomatic Problems   (Greece)

Author keywords

Colorectal cancer; Ibandronate; Metastatic bone disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IBANDRONIC ACID;

ADULT; ARTICLE; BONE TUMOR; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MIDDLE AGED; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COLORECTAL NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 35348976664     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2007.00808.x     Document Type: Article

References (19)

1. Benson A.B., III (1998) Therapy for advanced colorectal cancer. Seminars in Oncology 25 (Suppl. 2 11.
2. Blijham G.H. (1991) Chemotherapy of colorectal cancer. Anticancer Drugs 2, 233 245.
3. Body J.J., Diel I.J., Lichinitser M.R., Kreuser E.D., Dornoff W., Gorbunova V.A., Budde M., Bergstrom B. MF 4265 Study Group (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology 14, 1399 1405.
4. Body J.J., Diel I.J., Bell R., Pecherstorfer M., Lichinitser M.R., Lazarev A.F., Tripathy D. Bergstrom B. (2004a) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111, 306 312.
5. Body J.J., Diel I.J., Lichinitzer M., Lazarev A., Pecherstorfer M., Bell R., Tripathy D. Bergstrom B. (2004b) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. British Journal of Cancer 90, 1133 1137.
6. Chu K.C., Tarone R.E., Chow W.H., Hankey B.F. Ries L.A. (1994) Temporal patterns in colorectal cancer incidence, survival and mortality from 1950 through 1990. Journal of the National Cancer Institute 86, 997 1006.
7. Conley B.A., Kaplan R.S. Arbuck S.G. (1998) National Cancer Institute Clinical Trials Program in Colorectal Cancer. Cancer Chemotherapy Pharmacology 42, S75 S79.
8. Cunningham D. Findlay M. (1993) The chemotherapy of colon cancer can no longer be ignored. European Journal of Cancer 29A, 2077 2079.
9. Delva R., Pein F., Lorthoary A., Gamelin E, Cellier P Larra F. (1993) Bone metastases of colorectal cancers: apropos of 8 cases. La Revue de medecine interne 14, 223 228.
10. Hattori S., Miyakawa H., Okuda K., Kudo K. Noguchi T. (2004) Bisphosphonate as an adjuvant therapy for the pain of bone metastases. 3 Cases. Gan to Kagaku Ryoho 31, 271 274.
11. Landis S.H., Murray T., Bolden S. Wingo P.A. (1999) Cancer statistics 1999. CA: A Cancer Journal for Clinicians 49, 8 31.
12. Mayer R.J. (1992) Chemotherapy for metastatic colorectal cancer. Cancer 70 (Suppl. 1414 1424.
13. Meropol N.J. (1998) Oral fluoropyrimidines in the treatment of colorectal cancer. European Journal of Cancer 34, 1509 1513.
14. Midgley R. Kerr D. (1999) Colorectal cancer. Lancet 353, 391 399.
15. Parkin D.M., Pisani P. Ferlay J. (1999) Global cancer statistics. CA: A Cancer Journal for Clinicians 49, 33 64.
16. Pazdur R., Hoff P.M., Medgyesy D., Royce M. Brito R. (1998) The oral fluorouracil prodrugs. Oncology (Hunting) 12, 48 51.
17. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M., Coleman R.E., Reitsma D.J., Seaman J.J., Chen B.L. Ambros Y. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer Journal 7, 377 387.
18. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M.A., Coleman R.E., Reitsma D.J., Chen B.L. Seaman J.J. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, double-blind, multicenter, comparative trial. Cancer 98, 1735 1744.
19. Wingo P.A., Ries L.A., Parker S.L. Health C.W. Jr. (1998) Long-term cancer patient survival in the United States. Cancer Epidemiology, Biomarkers and Prevention 7, 271 282.